Overcome the challenges of measuring complement biomarkers with a validated ECL immunoassay.

Accurate quantification of complement biomarkers is essential for understanding immune responses, but measuring C3a and C3a desArg can be difficult due to their high endogenous levels and rapid conversion in plasma. This poster highlights the development and validation of a novel electrochemiluminescence (ECL) immunoassay designed to provide reliable quantitative measurement of these important complement proteins.

Key highlights include:

• Development and validation of a novel ECL immunoassay for C3a and C3a desArg
• Strategies for overcoming analytical challenges associated with complement biomarker measurement
• Evaluation of assay performance for quantitative analysis in human plasma
• Considerations for minimizing heat-induced complement activation during sample analysis
• Applications for complement biomarker testing in immunology research and clinical development

As complement biomarkers continue to play an important role in immunology and therapeutic research, robust analytical methods are essential for generating reliable data. Learn how a validated ECL immunoassay can improve the quantitative measurement of C3a and C3a desArg in human plasma.